A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Trial Profile

A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Leflutrozole (Primary)
  • Indications Hypogonadism
  • Focus Therapeutic Use
  • Sponsors Mereo BioPharma
  • Most Recent Events

    • 21 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
    • 19 Mar 2018 According to a Mereo BioPharma media release, the six-month safety extension study has fully enrolled 143 patients and results are expected in the fourth quarter of 2018.
    • 19 Mar 2018 Top-line results are presented in the Mereo BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top